Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...

The plaintiff is a neurosurgeon at the University of Virginia. He sued the University of Physicians Group alleging that a UVA ...

Oxygen therapy is a treatment going back to the days of Ben Franklin. In 1783, a French physician was the first to use it, ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.

Continued approval of zongertinib may be contingent upon verification of clinical benefit in a confirmatory trial.

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Analysts are estimating that Liquidia will report an earnings per share (EPS) of $-0.41. The market awaits Liquidia's announcement, with hopes high for news of surpassing estimates and providing ...

Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business ...

Cash, cash equivalents, marketable securities and restricted cash as of June 30, 2025, totaled approximately $408.2 million VYGLXIA NDA for spinocerebellar ataxia ...

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...